# Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

> **NCT04517526** · PHASE2 · UNKNOWN · sponsor: **Shanghai Cancer Hospital, China** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT

## Interventions

- **DRUG:** pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT

## Key facts

- **NCT ID:** NCT04517526
- **Lead sponsor:** Shanghai Cancer Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517526, "Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04517526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*